Product Information

APTENSIO XR 40 MG CAPSULE is a brand product labeled by Rhodes Pharmaceuticals L.P., priced at $7.9434 per EA under NDC 42858040545. Its NADAC has been published 271 times since Mar 21, 2018.

FDA first approved this application on Apr 17, 2015. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

APTENSIO XR 40 MG CAPSULE

methylphenidate hydrochloride
$7.9434per EA
DEA Schedule CII

Strength

40 mg/1

NDC

42858040545

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

2/18/2026

Approval Type

New Drug (NDA)

FDA Application

NDA205831

FDA Approved

4/17/2015

TE Code

AB3

On Market Since

4/17/2015

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulation

Price Statistics

The NADAC for APTENSIO XR 40 MG CAPSULE has been published 271 times since Mar 21, 2018, and over the history we have for it it has risen 14.9%. The table below summarizes its recorded NADAC range and movement.

Current price$7.9434 per EA
All-time high$8.0102 (Oct 16, 2024)
All-time low$6.9134 (Mar 21, 2018)
52-week high$7.9533
52-week low$7.9336
Median price$7.9434
Average price$7.8368
Largest weekly change+10.0% (Jun 6, 2018)
Weeks tracked271
Tracking sinceMar 21, 2018

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

-0.1%

3Y

-0.7%

5Y

-0.7%

All

+14.9%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 83% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of APTENSIO XR 40 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for APTENSIO XR 40 MG CAPSULE, manufactured by Rhodes Pharmaceuticals L.P., is $7.9434 per EA (NDC 42858040545), effective Aug 19, 2026.

How has the price of APTENSIO XR 40 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for APTENSIO XR 40 MG CAPSULE has risen 14.9%. It has been tracked across 271 weekly CMS publications since Mar 21, 2018.

What are the highest and lowest recorded NADAC prices for APTENSIO XR 40 MG CAPSULE?

Since Mar 21, 2018, the NADAC for APTENSIO XR 40 MG CAPSULE has ranged from a low of $6.9134 (Mar 21, 2018) to a high of $8.0102 (Oct 16, 2024), with a median of $7.9434 per EA.

Are there cheaper alternatives to APTENSIO XR 40 MG CAPSULE?

Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPHENIDATE CD 40 MG CAP, is $1.3833 per EA — about 83% below APTENSIO XR 40 MG CAPSULE.

Who manufactures APTENSIO XR 40 MG CAPSULE?

APTENSIO XR 40 MG CAPSULE (NDC 42858040545) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a brand product.